Power Spectral Analysis of EEG During Equi-MAC Inhalation Anesthesia
Launched by KANGBUK SAMSUNG HOSPITAL · Aug 15, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Volatile anesthetics vary in their relative hypnotic potency. Recent studies demonstrated that equi-minimum alveolar concentration of various volatile anesthetic agents may produce different spectral entropy or bispectral index values. However, there were no studies that demonstrate the difference of hypnotic potency using power spectral analysis of electroencephalographic signals (e.g., spectral edge frequency 95%, total power, % value of each bandage). The purpose of this clinical trial is to compare hypnotic effect of sevoflurane and desflurane at equal minimum alveolar concentrations us...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients undergoing arthroscopic knee surgery under general anesthesia using volatile anesthetics
- • patients with american society of anesthesiologist physical status I, II
- • patients aged 19-65 years
- • patients obtaining written informed consent
- Exclusion Criteria:
- • patients with a history of any psychiatric or neurological disease
- • patients who had received any medication affecting the central nervous system
- • patients who had received medication affecting the sympathetic or parasympathetic nervous systems
- • patients undergoing tracheal intubation for airway management
- • pregnant women
About Kangbuk Samsung Hospital
Kangbuk Samsung Hospital is a leading healthcare institution in South Korea, renowned for its commitment to advanced medical research and clinical excellence. As a sponsor of clinical trials, the hospital integrates cutting-edge technology and innovative therapies to enhance patient care and outcomes. With a multidisciplinary team of experienced researchers and healthcare professionals, Kangbuk Samsung Hospital is dedicated to conducting rigorous clinical studies that adhere to the highest ethical standards. Its focus on translational medicine aims to bridge the gap between laboratory findings and clinical applications, ultimately contributing to the advancement of medical science and improving therapeutic options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Kyoungho Ryu, M.D.
Principal Investigator
Kangbuk Samsung Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials